Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab biosimilar - Chia Tai Tianqing Pharmaceutical

Next Previous
Search
Drug Profile

Trastuzumab biosimilar - Chia Tai Tianqing Pharmaceutical

Alternative Names: TQ-B211

Latest Information Update: 23 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 23 Sep 2022 No development reported - Phase-III for Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in China (IV)
  • 11 Nov 2018 Phase-III clinical trials in Breast cancer (Combination therapy, Metastatic disease, First-line therapy) in China (IV) (NCT04385563)
  • 27 Oct 2017 Chia Tai Tianqing Pharmaceutical Group completes pharmacokinetic phase I trial (In volunteers) in China (NCT05765357)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top